Lawrence Berkeley National Laboratory masthead A-Z Index Berkeley Lab masthead U.S. Department of Energy logo Phone Book Jobs Search
Tech Transfer
Licensing Interest Form Receive Customized Tech Alerts

14-3-3 Sigma as a Biomarker of Basal Breast Cancer

IB-2594

APPLICATIONS OF TECHNOLOGY:

ADVANTAGES:

ABSTRACT:

The Patent Cooperation Treaty (PCT) patent application for this technolgy has been published (WO 2010/148370) and is available at www.wipo.int.

Mina Bissell and colleagues at Berkeley Lab have shown that 14-3-3 sigma expression correlates with acquisition of tumorigenicity and invasiveness, and that 14-3-3 sigma coordinates directional cell migration by directly inhibiting actin polymerization (in vitro and in situ) downstream of canonical signaling pathways, thus defining regions of actin assembly within cells. By immunohistochemical analysis, 14-3-3 sigma emerged as a highly sensitive and specific basal breast cancer biomarker which, when present, correlates with metastasis and poor outcome in independent patient cohorts. These data suggest that targeting 14-3-3 sigma-related actin cytoskeletal dynamics may benefit patients having the basal-like breast cancer subtype.

STATUS: Published PCT Patent Application WO 2010/148370 available at www.wipo.int.

SEE THESE OTHER BERKELEY LAB TECHNOLOGIES IN THIS FIELD:

Detecting and Treating Breast Cancer Resistance with EGFR Inhibitors, IB-2578

Native Cytokines for the Treatment of Advanced Breast Cancer and Other Tumors, JIB-2718

REFERENCE NUMBER: IB-2594

See More Biotech & Medicine Technologies
Last updated: 05/22/2012